The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Tue., Mar. 31, 5:42 AM

Slide #6. Insmed Incorporated Secondary Offering

Company: Insmed Incorporated (NASDAQ:INSM)
Date announced: 3/30/2015
Secondary Offering Details: Insmed Incorporated (NASDAQ:INSM) announced today that it has commenced an underwritten public offering of 10.0 million shares of its common stock. All of the shares of common stock in the offering are to be sold by Insmed.

Insmed develops and commercializes inhaled therapies for patients with lung diseases. Co.'s main product candidate, ARIKAYCE® (liposomal amikacin for inhalation), is an inhaled antibiotic treatment for lung infections. Co. is conducting a phase two clinical trial of ARIKAYCE in patients who have lung infections caused by non-tuberculous mycobacteria, and a two-year, open label safety study in patients that also completed its phase three clinical study of ARIKAYCE for cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pseudomonas) lung infections. Co. is also developing ARIKAYCE for Pseudomonas and other susceptible organisms causing lung infections in non-CF bronchiectasis patients.
Open the INSM Page at The Online Investor »

Company Name:  Insmed Inc
Website:  www.insmed.com
Sector:  Biotechnology
Number of ETFs Holding INSM:  16
Total Market Value Held by ETFs:  $65.11M
Total Market Capitalization:  $973.00M
% of Market Cap. Held by ETFs:  6.69%
 

Open the INSM Page at The Online Investor (in a new window) »

March 31, 2015    5:42 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
90th percentile
(ranked higher than approx. 90% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.